Insulin

HKBU research suggests potential of artemisinin derivative in treating human obesity

Retrieved on: 
Thursday, March 7, 2024

This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.

Key Points: 
  • This is the first time that artesunate is demonstrated to be able to treat obesity in a non-human primate, suggesting its therapeutic potential as a drug for treating human obesity.
  • However, patient compliance with exercise and dietary changes is often challenging, and many anti-obesity drugs are associated with adverse effects.
  • The researchers explored the therapeutic effect of artesunate on obesity using mice with diet-induced obesity.
  • "The research results provide hope for developing a novel treatment agent in response to the public health challenge of obesity, which warrants more extensive and effective interventions," he added.

The BioCollective® Awarded Groundbreaking Probiotic Patent

Retrieved on: 
Thursday, March 7, 2024

DENVER, March 7, 2024 /PRNewswire-PRWeb/ -- The BioCollective, a pioneer in microbiome research and consumer probiotics, today announced it has been granted a patent for a system of probiotics to manage and potentially treat a range of significant health issues.

Key Points: 
  • The issued composition-of-matter patent covers probiotic formulations to prevent or limit disease conditions, restore lost physiological function, and reduce gastrointestinal infection by modulating gastrointestinal mannitol.
  • The patent covers a range of clinical conditions, including diabetes, metabolic diseases, gastrointestinal infections, and neurological diseases.
  • The US Patent and Trademark Office issued US Patent No.
  • The company's BiotiQuest® Sugar Shift® probiotic and additional products in its development pipeline are covered under the patent.

Real-World Data Show Abbott's FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Retrieved on: 
Wednesday, March 6, 2024

These findings were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) held in Florence, Italy, on March 6, 2024.

Key Points: 
  • These findings were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) held in Florence, Italy, on March 6, 2024.
  • GLP-1 medicines – also known as glucagon-like peptide-1 receptor agonist (GLP-1 RA) - are increasingly being prescribed for people with Type 2 diabetes as they provide glycemic benefit and support weight loss.
  • "While treating my patients, I've observed that when we've added a CGM, like the FreeStyle Libre technology, to their GLP-1 therapy, we see even better glycemic control.
  • To maximize the benefits of GLP-1 medicines, it's worth considering the combination of a CGM to support people who live with Type 2 diabetes."

FDA Clears First Over-the-Counter Continuous Glucose Monitor

Retrieved on: 
Tuesday, March 5, 2024

SILVER SPRING, Md., March 5, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration cleared for marketing the first over-the-counter (OTC) continuous glucose monitor (CGM).

Key Points: 
  • SILVER SPRING, Md., March 5, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration cleared for marketing the first over-the-counter (OTC) continuous glucose monitor (CGM).
  • "CGMs can be a powerful tool to help monitor blood glucose.
  • The device presents blood glucose measurements and trends every 15 minutes in the accompanying app.
  • Data from a clinical study provided to the FDA showed that the device performed similarly to other iCGMs.

Svetlana Mojsov named 2024 recipient of the Pearl Meister Greengard Prize

Retrieved on: 
Wednesday, February 28, 2024

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Svetlana Mojsov , whose research into hormonal triggers for insulin production led to groundbreaking treatments for diabetes and obesity, will receive the 2024 Pearl Meister Greengard Prize, The Rockefeller University announced today.

Key Points: 
  • NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Svetlana Mojsov , whose research into hormonal triggers for insulin production led to groundbreaking treatments for diabetes and obesity, will receive the 2024 Pearl Meister Greengard Prize, The Rockefeller University announced today.
  • Mojsov, a research associate professor at Rockefeller, will be honored at a ceremony on campus on April 17.
  • The Pearl Meister Greengard Prize was established by the late Paul Greengard , the Vincent Astor Professor at Rockefeller, and his wife, the sculptor Ursula von Rydingsvard.
  • Visit this page to register for the Pearl Meister Greengard Prize ceremony and learn more about the award.

Precision Fermentation Alliance and Food Fermentation Europe Finalize a Refined Definition of Precision Fermentation

Retrieved on: 
Monday, February 26, 2024

WASHINGTON and BRUSSELS, Feb. 26, 2024 /PRNewswire/ -- The Precision Fermentation Alliance (PFA) and FFE (Food Fermentation Europe) announced a refined definition of Precision Fermentation.

Key Points: 
  • WASHINGTON and BRUSSELS, Feb. 26, 2024 /PRNewswire/ -- The Precision Fermentation Alliance (PFA) and FFE (Food Fermentation Europe) announced a refined definition of Precision Fermentation.
  • This collaborative effort aims to provide clarity on the unique characteristics of precision fermentation and its differentiation from other food production technologies.
  • The refined definition of Precision Fermentation highlights key distinctions, including:
    Leveraging bioengineering: Precision Fermentation (PF) stands apart from traditional/wild fermentation and natural breeding techniques by leveraging the latest bioengineering techniques.
  • For more information about the work of the Precision Fermentation Alliance and Food Fermentation Europe, please visit https://www.pfalliance.org/ and https://www.foodfermentation.eu

MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®

Retrieved on: 
Thursday, February 15, 2024

Secondary endpoints include change in fasting plasma glucose after 26 weeks and rate of hypoglycemic events.

Key Points: 
  • Secondary endpoints include change in fasting plasma glucose after 26 weeks and rate of hypoglycemic events.
  • The multi-center study evaluated Afrezza in combination with basal insulin vs. multiple daily injections (MDI) of insulin in children and adolescents aged 4-17 who are living with type 1 or type 2 diabetes.
  • “We are excited to reach this milestone in exploring the potential of Afrezza for a younger generation living with diabetes,” said Dr. Kevin Kaiserman, Senior Vice President, Clinical Development and Medical Affairs for MannKind Corporation.
  • “We expect to complete a primary endpoint analysis in the fourth quarter.”
    More information on the study details is available at: https://www.clinicaltrials.gov/study/NCT04974528

Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP

Retrieved on: 
Tuesday, February 13, 2024

SEATTLE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that Cell Stem Cell has published a paper titled “Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate.” The paper evaluated a transplant of Sana’s engineered allogeneic, hypoimmune (HIP)-modified pancreatic islet cells into a fully immunocompetent, diabetic non-human primate (NHP). These modified islet cells, which cluster into effective endocrine organoids, are termed “pseudo islet grafts” (p-islets). The results demonstrated that the HIP-modified p-islets engrafted following intramuscular injection and provided stable endocrine function, enabling insulin independence in the absence of immunosuppression.

Key Points: 
  • These modified islet cells, which cluster into effective endocrine organoids, are termed “pseudo islet grafts” (p-islets).
  • The results demonstrated that the HIP-modified p-islets engrafted following intramuscular injection and provided stable endocrine function, enabling insulin independence in the absence of immunosuppression.
  • This publication, along with the ongoing IST, will provide invaluable insights toward our stem cell derived product candidate, SC451.
  • It was thus demonstrated that the tightly controlled blood glucose levels and insulin independence was entirely due to well-functioning HIP p-islets.

Edgepark adding first-of-its kind, fully automated insulin delivery system to diabetes portfolio

Retrieved on: 
Tuesday, February 13, 2024

TWINSBURG, Ohio, Feb. 13, 2024 /PRNewswire/ -- Edgepark announced today it is offering the newly launched Beta Bionics iLet Bionic Pancreas fully automated insulin delivery (AID) system as part of its comprehensive diabetes management solution portfolio. The iLet is the first and only system that does not require carbohydrate counting* and fully automates 100 percent of insulin doses. Designed for anyone six years of age and older living with Type 1 diabetes, it eliminates the traditional manual work previously involved with using an insulin pump.

Key Points: 
  • TWINSBURG, Ohio, Feb. 13, 2024 /PRNewswire/ -- Edgepark announced today it is offering the newly launched Beta Bionics iLet Bionic Pancreas fully automated insulin delivery (AID) system as part of its comprehensive diabetes management solution portfolio.
  • The iLet is the first and only system that does not require carbohydrate counting* and fully automates 100 percent of insulin doses.
  • "Edgepark is thrilled to offer the iLet as a first-of-its-kind device that uses automation to make diabetes simpler to navigate."
  • As with any insulin delivery system, users must also be able to load the insulin pump with insulin, insert an infusion set and troubleshoot when challenges occur.

Tandem Diabetes Care Launches Tandem Mobi, the World’s Smallest, Durable Automated Insulin Delivery System

Retrieved on: 
Tuesday, February 13, 2024

(NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of its new Tandem Mobi, the world’s smallest, durable automated insulin delivery system for people living with diabetes.

Key Points: 
  • (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of its new Tandem Mobi, the world’s smallest, durable automated insulin delivery system for people living with diabetes.
  • View the full release here: https://www.businesswire.com/news/home/20240213214991/en/
    Tandem Mobi, the world’s smallest, durable insulin delivery system, now shipping in the United States.
  • The Tandem Customer Care team is available now to help determine eligibility and potential timing of pump shipments for customers.
  • People living with diabetes interested in the Tandem Mobi system can start the order process at: www.tandemdiabetes.com/mobi .